 |
The Journal of Neuroscience, August 23, 2006, 26(34):8800-8803; doi:10.1523/JNEUROSCI.2076-06.2006
Previous Article | Next Article 
Brief Communications
GABAB(1) Receptor Isoforms Differentially Mediate the Acquisition and Extinction of Aversive Taste Memories
Laura H. Jacobson,1
Peter H. Kelly,1
Bernhard Bettler,2
Klemens Kaupmann,1 and
John F. Cryan1,3
1Novartis Institutes for BioMedical Research, Novartis Pharma, CH-4002 Basel, Switzerland, 2Institute of Physiology, Department of Clinical-Biological Sciences, Pharmazentrum, University of Basel, CH-4056 Basel, Switzerland, and 3Department of Pharmacology and Therapeutics, School of Pharmacy, University College Cork, Cork, Ireland
Correspondence should be addressed to Dr. John F. Cryan at his present address: Department of Pharmacology and Therapeutics, School of Pharmacy, University College Cork, Cork, Ireland. Email: j.cryan{at}ucc.ie
Conditioned taste aversion (CTA) is a form of aversive memory in which an association is made between a consumed substance and a subsequent malaise. CTA is a critical mechanism for the successful survival, and hence evolution, of most animal species. The role of excitatory neurotransmitters in the neurochemical mechanisms of CTA is well recognized; however, less is known about the involvement of inhibitory receptor systems. In particular, the potential functions of metabotropic GABAB receptors in CTA have not yet been fully explored. GABAB receptors are metabotropic GABA receptors that are comprised of two subunits, GABAB(1) and GABAB(2), which form heterodimers. The Gabbr1 gene is transcribed into two predominant isoforms, GABAB(1a) and GABAB(1b), which differ in sequence primarily by the inclusion of a pair of sushi domains (also known as short consensus repeats) in the GABAB(1a) N terminus. The behavioral function of mammalian GABAB(1) receptor isoforms is currently unknown. Here, using a point mutation strategy in mice, we demonstrate that these two GABAB(1) receptor isoforms are differentially involved in critical components of CTA. In contrast to GABAB(1b)/ and wild-type mice, GABAB(1a)/ mice failed to acquire CTA. In contrast, GABAB(1b)/ mice robustly acquired CTA but failed to show any extinction of this aversion. The data demonstrate that GABAB receptors are involved in both the acquisition and extinction of CTA; however, receptors containing the GABAB(1a) or the GABAB(1b) isoform differentially contribute to the mechanisms used to learn and remember the salience of aversive stimuli.
Key words: conditioned taste aversion; GABAB; anxiety; inhibitory; learning; extinction
Received May 16, 2006;
revised June 28, 2006;
accepted July 11, 2006.
Correspondence should be addressed to Dr. John F. Cryan at his present address: Department of Pharmacology and Therapeutics, School of Pharmacy, University College Cork, Cork, Ireland. Email: j.cryan{at}ucc.ie
This article has been cited by other articles:

|
 |

|
 |
 
B. Royer-Zemmour, M. Ponsole-Lenfant, H. Gara, P. Roll, C. Leveque, A. Massacrier, G. Ferracci, J. Cillario, A. Robaglia-Schlupp, R. Vincentelli, et al.
Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR
Hum. Mol. Genet.,
December 1, 2008;
17(23):
3617 - 3630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Hefner, N. Whittle, J. Juhasz, M. Norcross, R.-M. Karlsson, L. M. Saksida, T. J. Bussey, N. Singewald, and A. Holmes
Impaired Fear Extinction Learning and Cortico-Amygdala Circuit Abnormalities in a Common Genetic Mouse Strain
J. Neurosci.,
August 6, 2008;
28(32):
8074 - 8085.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ulrich, V. Besseyrias, and B. Bettler
Functional Mapping of GABAB-Receptor Subtypes in the Thalamus
J Neurophysiol,
December 1, 2007;
98(6):
3791 - 3795.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. H. Jacobson, B. Bettler, K. Kaupmann, and J. F. Cryan
GABAB(1) Receptor Subunit Isoforms Exert a Differential Influence on Baseline but Not GABAB Receptor Agonist-Induced Changes in Mice
J. Pharmacol. Exp. Ther.,
December 1, 2006;
319(3):
1317 - 1326.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|